1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E52096BF1B04AC1500258B0A00291E93
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-establishing-mena-standards-field-medical-performance-excellence?opendocument
18
19opendocument
203.237.15.145
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB
Access. Intelligence. Excellence

| Advanced Search | 0
Research and Consulting Areas of Expertise

Benchmarking Reports Areas of Expertise Report Catalog FAQ
Best Practice Database Areas of Expertise New Research Case Analogs Benefits Types Of Research Current Members
Research and Advisory Services Areas of Expertise Digital Technology Consortium Field Medical Excellence Medical Affairs Consortium White Papers Research Partners Partnership Benefits Contact Us
Excellence Services Pharma and Medical Device Quality New Product Planning Medical Affairs Pharmaceutical Launch Market Research Competitive Intelligence

Industries

Biotechnology Financial Services Healthcare Medical Device Manufacturing Pharmaceuticals Technology and Communications

Functions

Brand Management & Product Leadership Competitive & Business Intelligence Commercial Operations Customer Service Clinical Operations Digital Technologies / AI Human Resources Medical Affairs Market Access Market Research, Analytics & Forecasting

 

Marketing Management Patient Access, Support, Insights and Operations Product Launch Pull Through Pharma Launch Playbook Scenario Planning / War Gaming Sales Supply Chain
Corporate Overview About Benchmarking Benchmarking Books What is a Best Practice? Research Methodology

Our Clients Testimonials

Our Team Careers Best Practices Interns Work at Best Practices, LLC Help Set Research Agenda
Follow Best Practices LLC linkedIn twitter slideshare youtube pinterest

Overview Press Releases Speaking Events Media Coverage Receive Research Updates Contact Us
Address/Email/Phone Schedule a Meeting
Report Catalog Videos
Database Member Home RAS Member Home

» Products & Services » » Medical Affairs » Field Medical Excellence

Establishing MENA Standards for Field Medical Performance Excellence

DB Image

Download FREE Excerpt

ID: 5803

Features:

9 Info Graphics

19 Data Graphics

300+ Metrics

9 Narratives

Pages/Slides: 33

Published: 2024

Delivery Format: Online PDF Document

 

License Options:


Buy Now

 

919-403-0251
Schedule a Meeting
Request a Quote


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Establishing MENA Standards for Field Medical Performance Excellence”

STUDY OVERVIEW

Maximizing the performance of field medical teams in the dynamic and diverse Middle East and North Africa (MENA) region is critical for organizations seeking to maintain a competitive edge. Biopharma organizations must deploy actionable strategies to optimize operations, maximize stakeholder engagement, and evaluate performance effectively.

Best Practices, LLC conducted benchmarking research to deliver critical insights to field medical leaders, empowering them to navigate challenges and capitalize on opportunities within the Middle East and North Africa (MENA) market. By delving into key insights and benchmarks, the study equips field medical leaders with the necessary knowledge and strategies to drive field medical performance excellence across MENA.


KEY TOPICS

  • Effective Field Performance Metrics in the MENA Region
  • Framework for Field Medical Excellence
  • KOL Targeting and Engagement Levels in the MENA Region
  • Average MSL Time Allocation for KOL Interactions and Internal Activities
  • MENA Region Field Medical Staffing Footprint
  • Key Lessons Learned for Measuring MSL Impact in the MENA Region

KEY METRICS

  • Average total panel size supported by an individual MSL in the MENA region
  • Average number of monthly KOL/HCP and F2F meetings in the MENA region
  • MSL’s average time spent per thought leader interaction in the MENA region
  • Value assigned to each interaction type on the MSL scorecard – MENA region
  • Key metrics for evaluating and demonstrating the value of MSLs in the MENA region
  • Engagement metrics for non-tiered KOLs in the MENA region
  • Average annual field presence of MSLs in the MENA region
  • Time spent by MSLs on external, internal and logistics activities in the MENA region
  • Weekly MSL time allocation across activity streams in the MENA region
  • MSL engagement mix in the MENA region
  • Average number of field staff members in the MENA region
  • Span of control: MSLs per MSL manager in the MENA region

SAMPLE KEY FINDINGS

  • MENA Engagement Focus: The MENA region prioritizes engagement with Key Opinion Leaders (KOLs), which represent 62% of the overall focus. Healthcare Professionals (HCPs) account for 31%, while payers and other stakeholders constitute 1% and 6%, respectively.

METHODOLOGY

This study offers tailored benchmarks and insights focused on the MENA region. The data from this study is drawn from a larger global pool of field leaders, featuring 448 survey responses from over 100 biopharma manufacturers across the world. The data is meticulously segmented at the regional level to offer nuanced insights.

Additionally, Best Practices, LLC utilizes its proprietary Field Medical Excellence database to provide additional benchmarks tailored to align with varied portfolio considerations.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

RELATED RESEARCH